Human Immunodeficiency Virus Clinical Trial
Official title:
Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model
Like most of sub-Saharan Africa, Rwandan youth are the epicenter of the AIDS epidemic, accounting for 40% of new infections. Antiretroviral (ART) adherence is a global health priority, but Rwandan youth are more than twice as likely to be on second line therapy than adults, and with a median population age of 18.7 years old, adherence is essential for Rwanda's future. Resources to provide youth-centered medical and psychosocial care are limited in Rwanda, and young people with HIV face many obstacles to adherence, namely the long-term consequences of genocide, depression, and gender-based violence, as well as logistical issues, negative attitudes, and insufficient parent/caregiver support. Preliminary data underscore the utility of culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) in reducing depression and traumatic distress among youth and adults in Rwanda. This project proposes a 2-arm randomized controlled trial (RCT) to test and compare the efficacy of adherence-enhanced Trauma Informed Cognitive Behavioral Therapy (i.e., TI-CBTe) to usual care in increasing ART adherence among Rwandan youth from two clinics caring for the largest number of youth with HIV in Rwanda. This proposal answers a compelling need for innovative programs to increase ART adherence among HIV+ youth. If effective, the study will build Rwanda's capacity to provide much needed services; and, involvement by the Rwanda Biomedical Center will ensure wide dissemination.
This study proposes a 2-arm, RCT to test and compare adherence-enhanced Trauma Informed
Cognitive Behavioral Therapy (TI-CBTe) to usual care on ART adherence among HIV+ Rwandan
youth. Based on a well-grounded theoretical framework, TI-CBTe blends a culturally adapted
empirically-supported intervention (TI-CBT) with strategies to increase ART adherence by
reducing depression, trauma, and gender based violence (GBV). 350 HIV+ 14-21 year olds will
be randomly assigned to TI-CBTe or usual care and the intervention will be delivered in small
groups of 8 - 10 over eight consecutive Sundays. Adult caregivers (where available) will
participate in two sessions to address adherence support for youth. Caregivers and youth will
complete assessments at baseline, 6 and 12 months. Consistent with the Indigenous Leader
Outreach Model (ILOM), HIV+ young adults who are > 95% ART adherent will be trained to
deliver TI-CBTe. An intent-to-treat analysis will be used and a combination of regression
techniques and other inferential statistical tests for contrasting means and proportions.
Treatment effects on adherence and mediators for youth participants will be examined, as well
as indigenous youth leaders. Treatment outcomes will be analyzed using logistic and linear
multiple regression models examining effects at 6- and 12- months separately, as well as a
combined model with random effects for repeated measurements across time.
Participants will be recruited from two clinics: WE-ACTx For Hope and Central University
Hospital of Kigali (CHUK), which are the primary providers of HIV care for infected
adolescents, and both have long-standing relationships with the community. Youth and
caregivers will be invited to meet with research staff if they are interested to inform them
about the project and request permission to be contacted by the research team. The
assent/consent forms will be reviewed with IYL, youth and caregivers, and trained staff will
administer questionnaires and interviews. Both sites have a staff psychologist who will
provide clinical backup in cases of mental health distress. Consent/assent forms will state
the exceptions to confidentiality, and where a youth reports child abuse or neglect or
suicidal ideation or attempts, the psychologist will be consulted. Indigenous youth leaders
(IYL), youth and caregivers will each complete the baseline and two follow-up assessments. A
month before follow-ups, IYL, youth and caregivers will be contacted to request their
participation in the next wave of data collection. Transportation will be offered and
interviews will be conducted at the clinics in a confidential location.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |